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Current medication selection for treatment of astronauts during spaceflight missions is primarily dictated by 
the task of efficiently treating the widest possible range of physiological conditions and illnesses with a 
limited set of medications. Dosage and recommendations on the combination of drugs are based on the 
assumption of genetically equal drug sensitivity and unchanged metabolism1,2. To our knowledge, there 
was no pre-flight drug sensitivity testing on a genetic level for any of the previous manned NASA space 
missions. Although many of the common, binary drug-drug interactions are, most likely, already 
considered in the ISS Medical kit composition, multi-drug and multi-drug-gene factors are not incorporated 
in the medication selection or prescription1,2. Furthermore, due to the physiological changes occurring in 
microgravity environments, astronauts might be susceptible to potential increased drug toxicity as a result 
of decreased clearance of numerous drugs. In particular, perturbation of CYP450 enzymes which contribute 
to the hepatic metabolism of the majority of drugs3,4 may have significant effects on therapeutic efficacy 
and increase treatment-related toxicity5. The genes encoding the CYP450 enzymes are highly variable in 
humans. Inheritable variations of CYP450 hepatic metabolizer enzymes and transport proteins play a 
crucial role in the inter-individual variability of drug efficiency and risks of adverse drug reactions5. 
Additionally, there are some reports that document changes in the levels of production of drug-
metabolizing enzymes in microgravity5,6,7. These data can be extrapolated to provide reasonable 
assumptions of decreased levels of expression for most CYP450 enzymes in human body during prolonged 
space travel. If the prescribed medication regiment is not fully effective or causes undesirable side effects, 
the ability of the astronauts to function and maintain peak performance levels during space flight could be 
seriously compromised. Therefore, technologies capable of predicting and managing medication side 
effects, interactions, and toxicity of drugs during spaceflight are needed. 
We propose to develop and customize for NASA’s applications available on the market Personalized 
Prescribing System (PPS) that would provide a comprehensive, non-invasive solution for safer, targeted 
medication management for every crew member resulting in safer and more effective treatment and, 
consequently, better performance. PPS will function as both decision support and record-keeping tool for 
flight surgeons and astronauts in applying the recommended medications for situations arising in flight. The 
information on individual drug sensitivity will translate into personalized risk assessment for adverse drug 
reactions and treatment failures for each drug from the medication kit as well as predefined outcome of any 
combination of them. Dosage recommendations will also be made individually. The mobile app will 
facilitate ease of use by crew and medical professionals during training and flight missions. 
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